Latest Benchmark shows 35% decline in antibiotics pipeline in past 5 years

The article provides context on the public health threat posed by antimicrobial resistance (AMR), noting that 12 years after the World Health Organization formally raised the alarm, drug resistance continues to grow.

It notes that despite numerous public and private incentives and initiatives, the pipeline of antibiotics in development is thinner than ever, highlighting the Benchmark’s finding that the antimicrobial pipeline from large, research-based pharmaceutical companies has declined by 35% since the release of the 2021 iteration of the report.